You are here: Industry Insights > TG Therapeutics

News List

Samsung Biologics scores large-scale ublituximab manufacturing deal cphi-online
May 24, 2021
TG Therapeutics secures long-term capacity to meet anticipated demand for promising investigational glycoengineered monoclonal antibody
Samsung Biologics, TG Therapeutics Expand Manufacturing Collaboration contractpharma
April 28, 2021
Samsung Biologics, a contract development and manufacturing organization (CDMO) and TG Therapeutics, are expanding a large-scale contract manufacturing deal for the supply of TG Therapeutics’ ublituximab, an investigational anti-CD20 monoclonal antibody.
TG Therapeutics’ ublituximab tops Sanofi’s Aubagio in MS trial pharmatimes
April 20, 2021
New York-headquartered biopharma company TG Therapeutics has revealed new data for its investigational therapy ublituximab, which demonstrated superiority over Sanofi’s Aubagio in patients with relapsing forms of multiple sclerosis (MS).
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Marginal Zone Lymphoma drugs
April 18, 2019
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation to its phosphoinositide-3-kinase (PI3K) delta inhibitor
TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting firstwordpharma
February 23, 2019
These data support the ongoing, fully enrolled, international Phase 3 program evaluating ublituximab (TG-1101) for the treatment of relapsing form of Multiple Sclerosis (RMS).